RESUMEN
Natural killer (NK) cells are a potent weapon against tumor and viral infection. Finding active compounds with the capacity of enhancing NK cell effector functions will be effective to develop new anti-cancer drugs. In this study, we initially screened 287 commercially available active compounds by co-culturing with peripheral blood mononuclear cells (PBMCs). We found that five compounds, namely, Daphnetin, MK-8617, LW6, JIB-04, and IOX1, increased the IFN-γ+ NK cell ratio in the presence of IL-12. Further studies using purified human primary NK cells revealed that Daphnetin directly promoted NK cell IFN-γ production in the presence of IL-12 but not IL-15, while the other four compounds acted on NK cells indirectly. Daphnetin also improved the direct cytotoxicity of NK cells against tumor cells in the presence of IL-12. Through RNA-sequencing, we found that PI3K-Akt-mTOR signaling acted as a central pathway in Daphnetin-mediated NK cell activation in the presence of IL-12. This was further confirmed by the finding that both inhibitors of PI3K-Akt and its main downstream signaling mTOR, LY294002, and rapamycin, respectively, can reverse the increase of IFN-γ production and cytotoxicity in NK cells promoted by Daphnetin. Collectively, we identify a natural product, Daphnetin, with the capacity of promoting human NK cell activation via PI3K-Akt-mTOR signaling in the presence of IL-12. Our current study opens up a new potential application for Daphnetin as a complementary immunomodulator for cancer treatments.
Asunto(s)
Citotoxicidad Inmunológica/efectos de los fármacos , Interferón gamma/biosíntesis , Células Asesinas Naturales/efectos de los fármacos , Activación de Linfocitos/efectos de los fármacos , Umbeliferonas/farmacología , Acetanilidas/farmacología , Adamantano/análogos & derivados , Adamantano/farmacología , Adolescente , Adulto , Aminopiridinas/farmacología , Evaluación Preclínica de Medicamentos , Inhibidores Enzimáticos/farmacología , Femenino , Humanos , Hidrazonas/farmacología , Hidroxiquinolinas/farmacología , Interferón gamma/genética , Interleucina-12/fisiología , Células K562 , Células Asesinas Naturales/inmunología , Leucocitos Mononucleares/efectos de los fármacos , Leucocitos Mononucleares/inmunología , Masculino , Persona de Mediana Edad , Fosfatidilinositol 3-Quinasas/fisiología , Proteínas Proto-Oncogénicas c-akt/fisiología , Piridazinas/farmacología , Pirimidinas/farmacología , Transducción de Señal , Serina-Treonina Quinasas TOR/fisiología , Adulto JovenRESUMEN
BACKGROUND: Bromodomain and extra-terminal (BET) proteins perform key roles in epigenetic control of gene expression that is involved in inflammatory conditions, including psoriasiform dermatitis (PsD). Predicting which (of many potential available BET inhibitors) will be effective in vivo is challenging. OBJECTIVE: We determine if a novel in vitro assay that includes two critical cell types involved in human psoriasis can predict the therapeutic potential of specific BET inhibitors in vivo. METHODS: An in vitro model consisting of U-937 and HaCaT cell co-culture was created to screen small molecule BET antagonists for inhibition of cutaneous inflammatory genes. Efficacious BET inhibitors were tested in a mouse imiquimod (IMQ)-induced PsD model. RESULTS: In the co-culture system, HaCaT cells exhibited a marked increase in the secretion of a characteristic set of proinflammatory and Th17-associated cytokines. Of the ten commercially-available small molecules targeting BET proteins assayed, most compounds exhibited inhibitory functions at 1 µM against inflammatory activation, but responded variably at lower concentrations. OTX015, a typical representative for most of the compounds, barely inhibited the inflammatory reactions at 0.1 µM. By contrast, ABBV075 was effective in concentrations as low as 0.01 µM. While oral administration OTX015 in IMQ-treated mice reduced disease severity, ABBV075 equally decreased the symptoms and molecular and cellular severity markers at one-tenth of the minimal dosing required for OTX015. CONCLUSION: In vitro screening system combined with an in vivo animal model, can serve as a convenient pre-clinical screening tool for the selection of BET inhibitors (and possibly other drugs) that may have clinical potential in psoriasis therapy.
Asunto(s)
Acetanilidas/farmacología , Epigénesis Genética/efectos de los fármacos , Compuestos Heterocíclicos con 3 Anillos/farmacología , Psoriasis/tratamiento farmacológico , Piridonas/farmacología , Piel/efectos de los fármacos , Sulfonamidas/farmacología , Acetanilidas/uso terapéutico , Administración Oral , Animales , Línea Celular Tumoral , Técnicas de Cocultivo , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Epigénesis Genética/inmunología , Femenino , Células HaCaT , Compuestos Heterocíclicos con 3 Anillos/uso terapéutico , Humanos , Imiquimod/administración & dosificación , Imiquimod/inmunología , Mediadores de Inflamación/metabolismo , Ratones , Monocitos , Psoriasis/inducido químicamente , Psoriasis/inmunología , Psoriasis/patología , Piridonas/uso terapéutico , Piel/inmunología , Piel/patología , Sulfonamidas/uso terapéuticoRESUMEN
AIMS: Neuromodulation (nerve stimulation) can produce analgesia. One form, bilateral pudendal nerve stimulation (bPNS), suppresses responses to urinary bladder distension (UBD) in hypersensitive rats. Drugs can modify this effect (eg, benzodiazepines, but not opioids, suppress bPNS effects). Prior to a clinical trial of bPNS effects on bladder pain, we felt it was prudent to survey the effects of medications commonly used in patients with bladder disorders. METHODS: Bladder hypersensitivity was produced by neonatal bladder inflammation in rat pups coupled with a second inflammatory insult as an adult. Antimuscarinic (oxybutynin), ß3 -adrenoceptor agonist (mirabegron, CL316243), α1 -adrenoceptor antagonist (tamsulosin), antidepressant (amitriptyline), muscle relaxing (baclofen), and sedative (propofol) agents were administered and effects of bPNS on responses to UBD assessed. bPNS consisted of bilateral biphasic electrical stimulation of the mixed motor/sensory component of the pudendal nerves. Visceromotor responses (VMRs; abdominal muscle contractile responses) were used as nociceptive endpoints. RESULTS: Many of these drugs directly inhibited the VMRs to UBD, but only mirabegron, at the doses employed, significantly reduced inhibitory effects of bPNS. In the presence of the other drugs, bPNS continued to produce statistically significant inhibition of VMRs to UBD. CONCLUSIONS: This study suggests that concurrent therapy with drugs used to treat bladder disorders could affect assessment of the effects of bPNS on bladder hypersensitivity. This study gives guidance to clinical trials using bPNS for the treatment of painful bladder syndromes and suggests potential clinical use of some of these medications in the treatment of these same disorders.
Asunto(s)
Cistitis/fisiopatología , Contracción Muscular/efectos de los fármacos , Nervio Pudendo/efectos de los fármacos , Agentes Urológicos/farmacología , Acetanilidas/farmacología , Animales , Terapia por Estimulación Eléctrica , Femenino , Ácidos Mandélicos/farmacología , Ratas , Ratas Sprague-Dawley , Tiazoles/farmacologíaRESUMEN
Hepatocellular carcinoma (HCC) is a biologically complex disease. Combination chemotherapy is a good strategy after surgery treatment. In this study, we report that berberine combined with HMQ1611 (BCH) had a good synergistic effect on the HCC. Our findings concluded that BCH showed good inhibition on the HCC proliferation and colony formation, which attributed to cell cycle arrest by BCH at G1 phase through impairing the expression of cyclinD1, cyclinE, and cdc2 and downregulated the phosphorylation of Akt, mTOR, and ERK. Moreover, BCH negatively regulated Wnt signaling pathway by upregulating the Axin and inhibiting the nuclear translocation of ß-catenin. BCH suppressed the phosphorylation of LRP5/6, GSK3ß, the expression of Wnt5a, Frizzled8, CK1, and APC, as well as the nucleus protein included MMP2, MMP3, MMP9, and c-myc. The above data of Wnt signaling regulators contributed to inhibition by BCH on cell migration. In vivo studies, BCH significantly suppressed the growth of SMMC-7721 xenograft tumors through downregulating Ki67 and ß-catenin, as well as upregulating Axin and p-ß-catenin. In conclusion, the results revealed that BCH exhibited potential antitumor activities against human liver cancer in vitro and in vivo, and the potential mechanism underlying these activities depended on the inhibition of the Wnt/ß-catenin signaling pathway.
Asunto(s)
Acetanilidas/farmacología , Benzamidas/farmacología , Berberina/farmacología , Carcinoma Hepatocelular/tratamiento farmacológico , Neoplasias Hepáticas/tratamiento farmacológico , Vía de Señalización Wnt/efectos de los fármacos , Animales , Carcinoma Hepatocelular/patología , Línea Celular Tumoral , Movimiento Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Sinergismo Farmacológico , Humanos , Neoplasias Hepáticas/patología , Masculino , Ratones , Ratones Endogámicos BALB C , beta Catenina/fisiologíaRESUMEN
Nonalcoholic steatohepatitis (NASH) is the form of nonalcoholic fatty liver disease that can evolve into cirrhosis. Lifestyle modifications achieving 10% weight loss reverse NASH, but there are no effective approved drug treatments. We previously identified defective adaptive thermogenesis as a factor contributing to metabolic syndrome and hepatic steatosis. We have now tested whether increasing nonshivering thermogenesis can improve preexisting NASH in mice. In high-fat diet-fed foz/foz mice with established NASH, treatment with ß3AR agonist restored brown adipose tissue (BAT) function, decreased body weight, improved glucose tolerance, and reduced hepatic lipid content compared to untreated counterparts, but had no impact on liver inflammation or on nonalcoholic fatty liver disease activity score (NAS). Similarly, ß3AR agonist did not alter liver pathology in other steatohepatitis models, including MCD diet-fed diabetic obese db/db mice. Caloric restriction alone alleviated the hepatic inflammatory signature in foz/foz mice. Addition of a ß3AR agonist to mice subjected to caloric restriction enhanced weight loss and glucose tolerance, and improved liver steatosis, hepatocellular injury, and further reduced liver inflammation. These changes contributed to a significantly lower NAS score such as no (0/9) animals in this group fulfilled the criteria for NASH pathology compared to eight out of ten mice under caloric restriction alone. In conclusion, ß3AR agonist counteracts features of the metabolic syndrome and alleviates steatosis, but does not reverse NASH. However, when coupled with weight loss therapy, BAT stimulation provides additional therapeutic advantages and reverses NASH.
Asunto(s)
Acetanilidas/uso terapéutico , Tejido Adiposo Pardo/efectos de los fármacos , Agonistas de Receptores Adrenérgicos beta 3/uso terapéutico , Dioxoles/uso terapéutico , Enfermedad del Hígado Graso no Alcohólico/tratamiento farmacológico , Tiazoles/uso terapéutico , Acetanilidas/farmacología , Agonistas de Receptores Adrenérgicos beta 3/farmacología , Animales , Restricción Calórica , Dieta Alta en Grasa/efectos adversos , Dioxoles/farmacología , Evaluación Preclínica de Medicamentos , Hígado/efectos de los fármacos , Síndrome Metabólico/tratamiento farmacológico , Ratones , Enfermedad del Hígado Graso no Alcohólico/dietoterapia , Enfermedad del Hígado Graso no Alcohólico/etiología , Tiazoles/farmacologíaRESUMEN
Mirabegron is a ß3-adrenoceptor agonist and released on the marked for the treatment of overactive bladder. Because mirabegron is the only ß3-adrenoceptor agonist available and substances that increase the levels of cyclic adenosine monophosphate (cAMP) inhibit platelet activity, we tested the hypothesis that mirabegron could have antiplatelet activity. Collagen- and thrombin induced platelet aggregation, thromboxane B2 (TXB2) and cyclic nucleotides quantification and calcium (Ca2+) mobilization were determined in the absence and presence of mirabegron in human washed platelets. Our results revealed that mirabegron (10-300⯵M) produced significant inhibitions on platelet aggregation induced by collagen- or thrombin, accompanied by greater intracellular levels of cAMP. The ß3-adrenoceptor antagonist L 748,337 (1⯵M) and the adenylate cyclase inhibitor, SQ 22,536 (100⯵M) reversed the inhibition induced by mirabegron in thrombin-stimulated platelets. The selective antagonists for ß1-and ß2-adrenoceptors, atenolol and ICI 117,551 (3⯵M), respectively did not interfere on the inhibition induced by mirabegron. In Fluo-4 loaded platelets, mirabegron reduced the total and intracellular Ca2+ levels. Pre-incubation with mirabegron almost abolished the levels of TXB2. Mirabegron did not augment the intracellular levels of cyclic guanosine monophosphate. In conclusion, mirabegron inhibited human platelet aggregation through cAMP accumulation, thus suggesting that substances that activate ß3-adrenoceptor could be beneficial as adjuvant antiplatelet therapy.
Asunto(s)
Acetanilidas/farmacología , Agonistas de Receptores Adrenérgicos beta 3/farmacología , AMP Cíclico/metabolismo , Agregación Plaquetaria/efectos de los fármacos , Receptores Adrenérgicos beta 3/metabolismo , Tiazoles/farmacología , Transporte Biológico/efectos de los fármacos , Calcio/metabolismo , Humanos , Tromboxano B2/metabolismoRESUMEN
Peripheral tissue inflammation or injury causes glutamate release from nociceptive axons, keratinocytes, and Schwann cells, resulting in thermal hypersensitivity. However, the detailed molecular mechanisms underlying glutamate-induced thermal hypersensitivity are unknown. The aim of this study was to clarify the involvement of peripheral transient receptor potential (TRP) TRP vanilloid 1 (TRPV1), TRP ankyrin 1 (TRPA1), and protein kinase C epsilon (PKCε) in glutamate-induced pain hypersensitivity. The amount of glutamate in the facial tissue was significantly increased 3 days after facial Complete Freund's adjuvant injection. The head-withdrawal reflex threshold to heat, cold, or mechanical stimulation was significantly decreased on day 7 after continuous glutamate or metabotropic glutamate receptor 5 (mGluR5) agonist (CHPG) injection into the facial skin compared with vehicle-injected rats, and glutamate-induced hypersensitivity was significantly recovered by mGluR5 antagonist MTEP, TRPA1 antagonist HC-030031, TRPV1 antagonist SB366791, or PKCε translocation inhibitor administration into the facial skin. TRPV1 and TRPA1 were expressed in mGluR5-immunoreactive (IR) trigeminal ganglion (TG) neurons innervating the facial skin, and mGluR5-IR TG neurons expressed PKCε. There was no significant difference in the number of GluR5-IR TG neurons among glutamate-injected, saline-injected, and naive rats, whereas that of TRPV1- or TRPA1-IR TG neurons was significantly increased 7 days after continuous glutamate injection into the facial skin compared with vehicle injection. PKCε phosphorylation in TG was significantly enhanced following glutamate injection into the facial skin. Moreover, neuronal activity of TG neurons was significantly increased following facial glutamate treatment. The present findings suggest that sensitization of TRPA1 and/or TRPV1 through mGluR5 signaling via PKCε is involved in facial thermal and mechanical hypersensitivity.
Asunto(s)
Hiperalgesia/metabolismo , Umbral del Dolor/fisiología , Receptor del Glutamato Metabotropico 5/metabolismo , Transducción de Señal/fisiología , Canal Catiónico TRPA1/metabolismo , Canales Catiónicos TRPV/metabolismo , Acetanilidas/farmacología , Animales , Modelos Animales de Enfermedad , Inhibidores Enzimáticos/farmacología , Adyuvante de Freund/toxicidad , Ácido Glutámico/metabolismo , Ácido Glutámico/toxicidad , Glicina/análogos & derivados , Glicina/farmacología , Hiperalgesia/etiología , Masculino , Neuronas/efectos de los fármacos , Neuronas/fisiología , Dolor/inducido químicamente , Dolor/complicaciones , Umbral del Dolor/efectos de los fármacos , Fenilacetatos/farmacología , Estimulación Física/efectos adversos , Purinas/farmacología , Piridinas/farmacología , Ratas , Ratas Sprague-Dawley , Piel/inervación , Canal Catiónico TRPA1/antagonistas & inhibidores , Canales Catiónicos TRPV/antagonistas & inhibidores , Tiazoles/farmacología , Ganglio del Trigémino/citologíaRESUMEN
RANKL and RANK are potential contributors of inflammatory cascade in human and animal model of arthritis. The current study aims to investigate the effect of N-(2-hydroxyphenyl)acetamide (NA-2) on regulation of RANKL pathway in collagen-induced arthritis (CIA) model in rats. CIA was induced using bovine type II collagen in female Wistar rats. The clinical parameters, level of pro-inflammatory and oxidative stress markers were measured to determine the progression of the disease. The mRNA level of RANKL and RANK and downstream mediators of inflammation i.e. c-fos, c-jun, NF-κB and Akt were analysed in spleen tissue using real-time PCR. Immunohistochemical analysis of iNOS, pAkt and c-Fos was also done in spleen tissue. Treatment with NA-2 and indomethacin showed increase in body weight and significant reduction in paw volume and arthritic score (p < 0.0001). Marked reduction in the level of oxidative stress markers, NO, PO and GSH (p < 0.0001), and pro-inflammatory markers, IL-1ß (p < 0.0001) and TNF-α (p < 0.01), was also observed. Likewise, NA-2 and indomethacin treatment also significantly suppressed the mRNA expression of RANKL, RANK, c-fos, c-jun, NF-κB (p < 0.0001) and Akt (p < 0.01) and protein expression of iNOS, pAkt and c-Fos (p < 0.0001) compared to the arthritic control group. Our findings suggest that NA-2 is an antiarthritic agent acting in a pleiotropic manner in CIA rats by not only reducing the clinical signs of arthritis, inflammatory cytokines and free radical production but also attenuating the RANK/RANKL signaling pathway.
Asunto(s)
Acetanilidas/farmacología , Artritis/metabolismo , Ligando RANK/metabolismo , Receptor Activador del Factor Nuclear kappa-B/metabolismo , Animales , Artritis/inducido químicamente , Artritis/tratamiento farmacológico , Biomarcadores/análisis , Colágeno , Femenino , Mediadores de Inflamación/metabolismo , Estrés Oxidativo/efectos de los fármacos , Ligando RANK/antagonistas & inhibidores , Ratas , Ratas Wistar , Receptor Activador del Factor Nuclear kappa-B/antagonistas & inhibidores , Transducción de Señal/efectos de los fármacos , Bazo/químicaRESUMEN
Reduction of hippocampal neurogenesis caused by aging and neurological disorders would impair neural circuits and result in memory loss. A new lead compound (N-trans-3',4'-methylenedioxystilben-4-yl acetamide 27) has been discovered to efficiently stimulate adult rats' neurogenesis. In-depth structure-activity relationship studies proved the necessity of a stilbene scaffold that is absent in highly cytotoxic analogs such as chalcones and heteroaryl rings and inactive analogs such as diphenyl acetylene and diphenyl ethane, and validated the importance of an NH in the carboxamide and a methylenedioxy substituent on the benzene ring. Immunohistochemical staining and biochemical analysis indicate, in contrast to previously reported neuroprotective chemicals, N-stilbenyl carboxamides have extra capacity for neuroproliferation-type neurogenesis, thereby providing a foundation for improving the plasticity of the adult mammalian brain.
Asunto(s)
Acetanilidas/farmacología , Descubrimiento de Drogas , Hipocampo/efectos de los fármacos , Neurogénesis/efectos de los fármacos , Extractos Vegetales/química , Estilbenos/farmacología , Acetanilidas/química , Acetanilidas/aislamiento & purificación , Animales , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Humanos , Masculino , Estructura Molecular , Ratas , Ratas Sprague-Dawley , Estilbenos/química , Estilbenos/aislamiento & purificación , Relación Estructura-ActividadRESUMEN
Anaplastic large cell lymphomas (ALCL) represent a peripheral T-cell lymphoma subgroup, stratified based on the presence or absence of anaplastic lymphoma kinase (ALK) chimeras. Although ALK-positive ALCLs have a more favorable outcome than ALK-negative ALCL, refractory and/or relapsed forms are common and novel treatments are needed. Here we investigated the therapeutic potential of a novel bromodomain inhibitor, OTX015/MK-8628 in ALK-positive ALCLs.The effects of OTX015 on a panel of ALK+ ALCL cell lines was evaluated in terms of proliferation, cell cycle and downstream signaling, including gene expression profiling analyses. Synergy was tested with combination targeted therapies.Bromodomain inhibition with OTX015 led primarily to ALCL cell cycle arrest in a dose-dependent manner, along with downregulation of MYC and its downstream regulated genes. MYC overexpression did not compensate this OTX015-mediated phenotype. Transcriptomic analysis of OTX015-treated ALCL cells identified a gene signature common to various hematologic malignancies treated with bromodomain inhibitors, notably large cell lymphoma. OTX015-modulated genes included transcription factors (E2F2, NFKBIZ, FOS, JUNB, ID1, HOXA5 and HOXC6), members of multiple signaling pathways (ITK, PRKCH, and MKNK2), and histones (clusters 1-3). Combination of OTX015 with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib led to cell cycle arrest then cell death, and combination with suboptimal doses of the ALK inhibitor CEP28122 caused cell cycle arrest. When OTX015 was associated with GANT61, a selective GLI1/2 inhibitor, C1156Y-resistant ALK ALCL growth was impaired.These findings support OTX015 clinical trials in refractory ALCL in combination with inhibitors of interleukin-2-inducible kinase or SHH/GLI1.
Asunto(s)
Acetanilidas/farmacología , Antineoplásicos/farmacología , Biomarcadores de Tumor/genética , Resistencia a Antineoplásicos/efectos de los fármacos , Compuestos Heterocíclicos con 3 Anillos/farmacología , Linfoma Anaplásico de Células Grandes/tratamiento farmacológico , Proteínas Tirosina Quinasas Receptoras/genética , Quinasa de Linfoma Anaplásico , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Puntos de Control del Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Sinergismo Farmacológico , Perfilación de la Expresión Génica/métodos , Regulación Neoplásica de la Expresión Génica , Predisposición Genética a la Enfermedad , Humanos , Concentración 50 Inhibidora , Linfoma Anaplásico de Células Grandes/genética , Linfoma Anaplásico de Células Grandes/patología , Fenotipo , Transducción de Señal/efectos de los fármacos , Factores de Tiempo , TranscriptomaRESUMEN
We demonstrate a novel dual strategy against inflammation and pain through body-wide desensitization of nociceptors via TRPA1. Attenuation of experimental colitis by capsazepine (CPZ) has long been attributed to its antagonistic action on TRPV1 and associated inhibition of neurogenic inflammation. In contrast, we found that CPZ exerts its anti-inflammatory effects via profound desensitization of TRPA1. Micromolar CPZ induced calcium influx in isolated dorsal root ganglion (DRG) neurons from wild-type (WT) but not TRPA1-deficient mice. CPZ-induced calcium transients in human TRPA1-expressing HEK293t cells were blocked by the selective TRPA1 antagonists HC 030031 and A967079 and involved three cysteine residues in the N-terminal domain. Intriguingly, both colonic enemas and drinking water with CPZ led to profound systemic hypoalgesia in WT and TRPV1(-/-) but not TRPA1(-/-) mice. These findings may guide the development of a novel class of disease-modifying drugs with anti-inflammatory and anti-nociceptive effects.
Asunto(s)
Analgésicos/farmacología , Antiinflamatorios/farmacología , Señalización del Calcio/efectos de los fármacos , Capsaicina/análogos & derivados , Dolor/tratamiento farmacológico , Aceites de Plantas/farmacología , Canal Catiónico TRPA1/metabolismo , Acetanilidas/farmacología , Animales , Capsaicina/farmacología , Células HEK293 , Humanos , Inflamación/tratamiento farmacológico , Inflamación/genética , Inflamación/metabolismo , Ratones , Ratones Noqueados , Planta de la Mostaza , Oximas/farmacología , Dolor/genética , Dolor/metabolismo , Purinas/farmacología , Canal Catiónico TRPA1/antagonistas & inhibidores , Canal Catiónico TRPA1/genéticaRESUMEN
OBJECTIVE: To examine the effects of mirabegron, a selective ß3 -adrenoceptor agonist that has recently been approved for the treatment of overactive bladder (OAB), on erectile function. Stimulation of ß3 -adrenoceptors localised in cavernosal smooth muscle cells may play a physiological role in mediating penile erection, and offer a beneficial pharmacological action for patients who have OAB and erectile dysfunction (ED). MATERIALS AND METHODS: Corpus cavernosal (CC) specimens were obtained from patients with ED and Peyronie's disease undergoing penile prosthesis implantation. Erectile responses were also evaluated in vivo after intracavernosal injection (ICI) of mirabegron in anaesthetised rats. Mirabegron-elicited relaxation responses (10(-8) -10(-3) m) on phenylephrine-induced contraction were seen in human CC (HCC) and rat CC strips in isolated organ-bath studies. The effects of inhibitors, namely L-NAME [N(G) -nitro-L-arginine methyl ester, a competitive inhibitor of nitric oxide synthase (NOS), 100 µm], ODQ [1H-(1,2,4) oxadiazolo(4,3-α) quinoxalin-1-one, a soluble guanylyl cyclase (sGC) inhibitor, 30µm], methylene blue (a NOS and sGC inhibitor, 20µm), SR59230A (ß3 -adrenoceptor blocker, 1 µm), and fasudil [Rho-associated protein kinase (ROCK) inhibitor, 0.1 µm], on mirabegron-induced relaxation responses were evaluated. Responses to mirabegron were compared with responses to isoprenaline and nebivolol. Immunohistochemistry was used to localise ß3 -adrenoceptors and ROCK in CC smooth muscle cells. In vivo rat data were expressed as intracavernosal pressure (ICP)/mean arterial pressure, and total ICP. RESULTS: Mirabegron resulted in a relaxation of phenylephrine-evoked CC contractions in a concentration-dependent manner and SR59230A antagonised the mirabegron-induced relaxations in HCC and rat CC. Other inhibitors, L-NAME, ODQ, and methylene blue, did not affect the mirabegron-induced relaxation responses. Mirabegron relaxation responses at concentrations (0.1-10 µm) were enhanced by fasudil (ROCK inhibitor) in rat but not in HCC strips. KCl-induced contractions in HCC and rat CC were partially inhibited by mirabegron. In vivo, ICI of mirabegron (doses of 0.1-1 mg/kg) had a minor effect on ICP when compared with vehicle administration. Immunohistochemistry data showed ß3 -adrenoceptors localised in the smooth muscle cells of the HCC and rat CC. CONCLUSIONS: Mirabegron markedly relaxed isolated CC strips by activating ß3 -adrenoceptors independently of the NO-cGMP pathway. There is also evidence of the existence of a close functional link between ß3 -adrenoceptors and the RhoA/ROCK pathway. These results may support further clinical studies using combinations of mirabegron with ROCK and phosphodiesterase type 5 inhibitors (PDE5i) for the treatment of ED, especially in patients who do not respond to PDE5i therapy.
Asunto(s)
Acetanilidas/farmacología , Agonistas de Receptores Adrenérgicos beta 3/farmacología , Disfunción Eréctil/tratamiento farmacológico , Relajación Muscular/efectos de los fármacos , Pene/efectos de los fármacos , Tiazoles/farmacología , Acetanilidas/uso terapéutico , Agonistas de Receptores Adrenérgicos beta 3/uso terapéutico , Animales , Humanos , Masculino , Ratas , Ratas Sprague-Dawley , Tiazoles/uso terapéuticoRESUMEN
Transient receptor potential ankyrin subtype 1 (TRPA1) channels are chemosensitive to compounds such as allyl isothiocyanate (AITC, the active component of mustard oil) and other reactive electrophiles and may also be thermodetectors in many animal phyla. In this study, we provide the first pharmacological evidence of a putative TRPA1-like channel in the medicinal leech. The leech's polymodal nociceptive neuron was activated by both peripheral and central application of the TRPA1 agonist AITC in a concentration-dependent manner. Responses to AITC were inhibited by the selective TRPA1 antagonist HC030031, but also by the TRPV1 antagonist SB366791. Other TRPA1 activators - N-methylmaleimide (NMM) and cinnamaldehyde (CIN) - also activated this nociceptive neuron, although HC030031 only inhibited the effects of NMM. The polymodal nociceptive neurons responded to moderately cold thermal stimuli (<17°C) and these responses were blocked by HC030031. AITC sensitivity was also found in the pressure-sensitive sensory neurons and was blocked by HC030031, but not by SB366791. AITC elicited a nocifensive withdrawal of the posterior sucker in a concentration-dependent manner that could be attenuated with HC030031. Peripheral application of AITC in vivo also produced swimming-like behavior that was attenuated by HC030031. These results suggest the presence of a TRPA1-like channel in the medicinal leech nervous system that responds to cold temperatures and may interact with the leech TRPV-like channel.
Asunto(s)
Hirudo medicinalis/efectos de los fármacos , Nociceptores/efectos de los fármacos , Canales Catiónicos TRPV/antagonistas & inhibidores , Acetanilidas/farmacología , Acroleína/análogos & derivados , Acroleína/farmacología , Anilidas/farmacología , Animales , Conducta Animal/efectos de los fármacos , Cinamatos/farmacología , Frío , Hirudo medicinalis/fisiología , Isotiocianatos/farmacología , Maleimidas/farmacología , Nociceptores/fisiología , Purinas/farmacología , Células Receptoras Sensoriales/efectos de los fármacos , Células Receptoras Sensoriales/fisiología , Canales Catiónicos TRPV/fisiologíaRESUMEN
An experiment has been conducted under laboratory conditions to investigate the residual effect of three pre-emergence herbicides (thiobencarb, pendimethalin and pretilachlor) at fivefold field application rates (7.5, 10.0 and 2.5 kg a.i. ha(-1), respectively), on the changes of microbial activities and some biochemical processes in the Gangetic alluvial soil of West Bengal. Application of herbicides in general significantly increased microbial biomass resulting in greater mineralization of C, N and P in soil. The highest stimulation of microbial biomass C was recorded with thiobencarb (24.4%) followed by pendimethalin (23.4%). Microbial biomass N was highly induced under pretilachlor (54.5%) and thiobencarb (52.7%), while the stimulation of microbial biomass P was at par in the herbicide-treated soils. Compared to untreated control, the highest amount of organic C was retained with thiobencarb followed by pendimethalin. A similar trend was recorded with thiobencarb for total N, while pendimethalin induced exchangeable NH4 (+) and soluble NO3 (-) to the highest extent (42.2 and 34.5%, respectively). Regarding the availability of P in soil, pretilachlor manifested greater stimulation (33.1%) than thiobencarb (21.6%) and pendimethalin (11.4%). As compared to untreated control, thiobencarb harboured maximum number of bacteria (107.9%), while pretilachlor exerted the highest stimulations towards the proliferations of actinomycetes (132.6%) and fungi (149.5%) in soil.
Asunto(s)
Bacterias/efectos de los fármacos , Hongos/efectos de los fármacos , Herbicidas/farmacología , Consorcios Microbianos/efectos de los fármacos , Microbiología del Suelo , Acetanilidas/farmacología , Compuestos de Anilina/farmacología , Biomasa , Carbono/metabolismo , Monitoreo del Ambiente , India , Nitrógeno/metabolismo , Fósforo/metabolismo , Suelo/química , Tiocarbamatos/farmacologíaRESUMEN
Transient receptor potential ankyrin1 (TRPA1) and transient receptor potential vanilloid 1 (TRPV1) are members of the TRP superfamily of structurally related, nonselective cation channels and mediators of several signaling pathways. Previously, we identified methyl syringate as an hTRPA1 agonist with efficacy against gastric emptying. The aim of this study was to find hTRPA1 and/or hTRPV1 activators in Agastache rugosa (Fisch. et Meyer) O. Kuntze (A.rugosa), commonly known as Korean mint to improve hTRPA1-related phenomena. An extract of the stem and leaves of A.rugosa (Labiatae) selectively activated hTRPA1 and hTRPV1. We next investigated the effects of commercially available compounds found in A.rugosa (acacetin, 4-allylanisole, p-anisaldehyde, apigenin 7-glucoside, L-carveol, ß-caryophyllene, trans-p-methoxycinnamaldehyde, methyl eugenol, pachypodol, and rosmarinic acid) on cultured hTRPA1- and hTRPV1-expressing cells. Of the ten compounds, L-carveol, trans-p-methoxycinnamaldehyde, methyl eugenol, 4-allylanisole, and p-anisaldehyde selectively activated hTRPA1, with EC50 values of 189.1±26.8, 29.8±14.9, 160.2±21.9, 1535±315.7, and 546.5±73.0 µM, respectively. The activities of these compounds were effectively inhibited by the hTRPA1 antagonists, ruthenium red and HC-030031. Although the five active compounds showed weaker calcium responses than allyl isothiocyanate (EC50=7.2±1.4 µM), our results suggest that these compounds from the stem and leaves of A.rugosa are specific and selective agonists of hTRPA1.
Asunto(s)
Agastache/química , Proteínas del Tejido Nervioso/agonistas , Canales de Potencial de Receptor Transitorio/agonistas , Acetanilidas/farmacología , Derivados de Alilbenceno , Anisoles/farmacología , Benzaldehídos/farmacología , Canales de Calcio , Línea Celular , Monoterpenos Ciclohexánicos , Eugenol/análogos & derivados , Eugenol/farmacología , Células HEK293 , Humanos , Monoterpenos/farmacología , Proteínas del Tejido Nervioso/antagonistas & inhibidores , Extractos Vegetales/farmacología , Hojas de la Planta/química , Tallos de la Planta/química , Sesquiterpenos Policíclicos , Purinas/farmacología , Rojo de Rutenio/farmacología , Sesquiterpenos/farmacología , Canal Catiónico TRPA1 , Canales Catiónicos TRPV/agonistas , Canales de Potencial de Receptor Transitorio/antagonistas & inhibidoresRESUMEN
Due to health concerns about phthalate esters, the use of alternative plasticizers is being considered. Phthalate esters enhance skin sensitization to fluorescein isothiocyanate (FITC) in mouse models. We have demonstrated that phthalate esters stimulate transient receptor potential ankyrin 1 (TRPA1) cation channels expressed on sensory neurons. We also found a correlation between TRPA1 activation and the enhancing effect on FITC-induced contact hypersensitivity (CHS) when testing various types of phthalate esters. Here we investigated the effects of an alternative plasticizer, diisopropyl adipate (DIA). Activation of TRPA1 by DIA was demonstrated by calcium mobilization using Chinese hamster ovary cells expressing TRPA1 in vitro. The effect of DIA was inhibited by a TRPA1-specific antagonist, HC-030031. The presence of DIA or dibutyl phthalate (DBP; positive control) during skin sensitization of BALB/c mice to FITC augmented the CHS response, as revealed by the level of ear-swelling. The enhancing effect of DIA was inhibited by in vivo pretreatment with HC-030031. FITC-presenting CD11c(+) dendritic cell (DC)-trafficking to draining lymph nodes was facilitated both by DIA and by DBP. DBP and DIA were similarly active in the enhancement of interferon-γ production by draining lymph nodes, but the effect on interleukin-4 production was weaker with DIA. Overall, DIA activated TRPA1 and enhanced FITC-induced CHS, as DBP did. The adjuvant effects of adipate esters may need to be considered because they are used as ingredients in cosmetics and drug formulations topically applied to the skin.
Asunto(s)
Adipatos/farmacología , Adyuvantes Inmunológicos/farmacología , Dermatitis por Contacto/inmunología , Plastificantes/farmacología , Canales de Potencial de Receptor Transitorio/inmunología , Acetanilidas/farmacología , Animales , Células CHO , Calcio/metabolismo , Cricetulus , Citocinas/inmunología , Células Dendríticas/efectos de los fármacos , Células Dendríticas/inmunología , Dermatitis por Contacto/etiología , Femenino , Fluoresceína-5-Isotiocianato , Ganglios Linfáticos/efectos de los fármacos , Ganglios Linfáticos/inmunología , Ratones Endogámicos BALB C , Purinas/farmacología , Canal Catiónico TRPA1 , Canales de Potencial de Receptor Transitorio/antagonistas & inhibidores , Canales de Potencial de Receptor Transitorio/genéticaRESUMEN
Peroxisome proliferator activated receptors-α (PPAR-α) control the expression of several genes involved in diseases like diabetes, hyperlipidaemia, and inflammatory disorders. Herein, we report the biological evaluation of recently identified hits from pharmacophore based virtual screening. The most potent hits, ZINC17167211, ZINC06472206 and ZINC08438472 showed EC50 values of 0.16, 1.1 and 12.1nM in PPAR-α agonist assay, respectively. Further, comparative docking and molecular dynamics analysis of selective PPAR-α agonists revealed that Thr279, Ala333, Lys358 and Met325 residues play an important role in the selective PPAR-α agonistic activity. The insights from docking and molecular dynamic studies will serve as a guideline for the development of potent and selective PPAR-α agonists.
Asunto(s)
Acetanilidas/química , Acetanilidas/farmacología , Compuestos de Anilina/química , Compuestos de Anilina/farmacología , Diseño de Fármacos , Evaluación Preclínica de Medicamentos/métodos , Simulación de Dinámica Molecular , PPAR alfa/agonistas , Ácidos Ftálicos/química , Ácidos Ftálicos/farmacología , Tiazolidinedionas/química , Tiazolidinedionas/farmacología , Tiofenos/química , Tiofenos/farmacología , para-Aminobenzoatos/química , para-Aminobenzoatos/farmacología , Técnicas Químicas Combinatorias , Humanos , Modelos Moleculares , Simulación del Acoplamiento Molecular , Estructura Molecular , Relación Estructura-ActividadRESUMEN
AIMS: We measured single-unit mechanosensitive afferent activities (SAAs) during reflexic, rhythmic bladder contractions (RBCs), and examined whether L-arginine, an NO substrate, and mirabegron, a ß3-adrenoceptor agonist, and oxybutynin, an antimuscarinic agent, can affect the SAAs in such condition. METHODS: Twenty-nine female Sprague-Dawley rats were anesthetized. SAA was identified by electro-stimulation of the left pelvic nerve and by bladder distension, and was divided into Aδ- or C-fibers by conduction velocity. To produce the RBCs, right L6 dorsal roots were kept intact. Under an isovolumetric condition, vehicle and L-arginine (300 mg/kg) or mirabegron (1 mg/kg) or oxybutynin (1 mg/kg) were administered intravenously. RESULTS: All of the Aδ- (n = 26) and C-fibers (n = 29) capable of responding to bladder distention were also responsive to bladder contractions during RBCs. The amplitude and duration of RBCs significantly decreased after mirabegron- and oxybutynin-administrations, but not after L-arginine-administration. The interval of RBC was significantly elongated after L-arginine- and mirabegron-administrations. Regarding the SAAs, the peaks of firing rate (FR) during RBCs and FR during the non-contractile phase were decreased after L-arginine-administration, which were more remarkable for Aδ-fibers than C-fibers. Similar results were observed after mirabegron-administration only for Aδ-fibers. After oxybutynin-administration, the peak of FR of both fiber-SAAs significantly decreased, but the change was not significant when the value was normalized by the amplitude of RBCs. CONCLUSIONS: The present results indicate that mechanosensitive Aδ- and C-fibers were also responsive to bladder contractions, and that NO production and ß3-adrenoceptor stimulation can inhibit SAAs mainly of Aδ-fibers synchronized with RBCs.
Asunto(s)
Acetanilidas/farmacología , Agonistas de Receptores Adrenérgicos beta 3/farmacología , Arginina/farmacología , Ácidos Mandélicos/farmacología , Antagonistas Muscarínicos/farmacología , Contracción Muscular/efectos de los fármacos , Músculo Liso/efectos de los fármacos , Neuronas Aferentes/efectos de los fármacos , Periodicidad , Reflejo/efectos de los fármacos , Tiazoles/farmacología , Vejiga Urinaria/efectos de los fármacos , Animales , Estimulación Eléctrica , Femenino , Mecanotransducción Celular/efectos de los fármacos , Músculo Liso/inervación , Músculo Liso/metabolismo , Fibras Nerviosas Mielínicas/efectos de los fármacos , Fibras Nerviosas Amielínicas/efectos de los fármacos , Óxido Nítrico/metabolismo , Presión , Ratas Sprague-Dawley , Factores de Tiempo , Vejiga Urinaria/inervación , Vejiga Urinaria/metabolismoRESUMEN
Cardiovascular effects of the linalool-rich essential oil of Aniba rosaeodora (here named as EOAR) in normotensive rats were investigated. In anesthetized rats, intravenous (i.v.) injection of EOAR induced dose-dependent biphasic hypotension and bradycardia. Emphasis was given to the first phase (phase 1) of the cardiovascular effects, which is rapid (onset time of 1-3 s) and not observed in animals submitted to bilateral vagotomy or selective blockade of neural conduction of vagal C-fibre afferents by perineural treatment with capsaicin. Phase 1 was also absent when EOAR was directly injected into the left ventricle injection, but it was unaltered by i.v. pretreatment with capsazepine, ondansetron or HC030031. In conscious rats, EOAR induced rapid and monophasic hypotensive and bradycardiac (phase 1) effects that were abolished by i.v. methylatropine. In endothelium-intact aortic rings, EOAR fully relaxed phenylephrine-induced contractions in a concentration-dependent manner. The present findings reveal that phase 1 of the bradycardiac and depressor responses induced by EOAR has a vago-vagal reflex origin resulting from the vagal pulmonary afferents stimulation. Such phenomenon appears not to involve the recruitment of C-fibre afferents expressing 5HT3 receptors or the two chemosensory ion channels TRPV1 and TRPA1 . Phase 2 hypotensive response appears resulting from a direct vasodilatory action.
Asunto(s)
Presión Sanguínea/efectos de los fármacos , Lauraceae/química , Monoterpenos/farmacología , Aceites Volátiles/farmacología , Reflejo/efectos de los fármacos , Acetanilidas/farmacología , Monoterpenos Acíclicos , Animales , Aorta/efectos de los fármacos , Derivados de Atropina/farmacología , Bradicardia/inducido químicamente , Capsaicina/análogos & derivados , Capsaicina/farmacología , Hipotensión/inducido químicamente , Técnicas In Vitro , Masculino , Ondansetrón/farmacología , Fenilefrina/farmacología , Aceites de Plantas/farmacología , Purinas/farmacología , Ratas , Ratas WistarRESUMEN
The transient receptor potential ankyrin 1 (TRPA1) ion channel on peripheral terminals of nociceptive primary afferent nerve fibres contributes to the transduction of noxious stimuli to electrical signals, while on central endings in the spinal dorsal horn, it amplifies transmission to spinal interneurons and projection neurons. The centrally propagating nociceptive signal that is induced and amplified by TRPA1 not only elicits pain sensation but also contributes to peripheral neurogenic inflammation through a peripheral axon reflex or a centrally mediated back propagating dorsal root reflex that releases vasoactive agents from sensory neurons in the periphery. Endogenous TRPA1 agonists that are generated under various pathophysiological conditions both in the periphery and in the spinal cord have TRPA1-mediated pro-nociceptive and pro-inflammatory effects. Among endogenous TRPA1 agonists that have been shown to play a role in the pathogenesis of pain and inflammatory conditions are, for example, methylglyoxal, 4-hydroxynonenal, 12-lipoxygenase-derived hepoxilin A3, 5,6-epoxyeicosatrienoic acid and reactive oxygen species, while mustard oil and cinnamaldehyde are most commonly used exogenous TRPA1 agonists in experimental studies. Among selective TRPA1 antagonists are HC-030031, A-967079, AP-14 and Chembridge-5861528. Recent evidence indicates that TRPA1 plays a role also in transition of acute to chronic pain. Due to its location on a subpopulation of pain-mediating primary afferent nerve fibres, blocking the TRPA1 channel is expected to have antinociceptive, antiallodynic and anti-inflammatory effects.